摘要
癌症是造成死亡的主要原因,且新的癌症病例每年的发病率在全球范围内不断上升。由于现行的抗癌药物的耐药性和副作用的频繁发生,使得寻求具有改进的治疗功能的新药的需求更加迫切。与过去的细胞毒性化疗相比,靶向化疗的概念试图通过攻击肿瘤相关机制来提高治疗的特异性。中心体簇的抑制作用代表了一种新兴的治疗理念。中心体调节有丝分裂纺锤体的行成确保染色体均匀分离到子细胞。许多肿瘤含有异常中心体,它通过多极有丝分裂纺锤体的行成导致非整倍性诱导。由于主轴多极化导致细胞死亡,肿瘤细胞发达的中心体簇机制通过联合两种功能的纺锤体来避免多极纺锤体的形成。中心体簇的抑制代表了一种新的药物开发的策略,且导致了多极纺锤体形成和随后的细胞死亡。在这篇综述中,我们报道了中心体簇的生物学理解方面的最新知识及能够诱导多极纺锤体形成的化合物例如indolquinolizines,整合素连接激酶抑制剂(QLT-0267),noscapinoids(EM011),邻苯二酰胺衍生物(TC11),灰黄霉素,菲啶(PJ-34),CCC1-01,CW069 GF-15,秋水仙胺,诺考达唑,紫杉醇,和长春碱。我们也展示了化合物绑定到γ-微管蛋白上的在中心体簇抑制范围下的电脑模拟结果。我们观察到GF-15的最大约束功效,CW069,紫杉醇和larotaxel与FG-15展示了最小的能量,分别是-8.4Kcal/mol和0.7uMPki。
关键词: 癌症,中心体簇,多极纺锤体诱导物,天然产物,异常中心体
Current Medicinal Chemistry
Title:Dis-organizing Centrosomal Clusters: Specific Cancer Therapy for a Generic Spread?
Volume: 22 Issue: 6
Author(s): D. Bhakta-Guha, M.E.M. Saeed, H.J. Greten and T. Efferth
Affiliation:
关键词: 癌症,中心体簇,多极纺锤体诱导物,天然产物,异常中心体
摘要: Cancer is a leading cause of mortality and the annual incidence of new cancer cases is rising worldwide. Due to the frequent development of resistance and the side effects of established anti-cancer drugs, the quest for new drugs with improved therapeutic features goes on. In contrast to cytotoxic chemotherapy of the past, the concept of targeted chemotherapy attempts to increase specificity of therapy by attacking tumor-related mechanisms. A novel emerging treatment concept represents the inhibition of centrosomal clustering. The centrosome regulates mitotic spindle formation assuring uniform separation of chromosomes to daughter cells. Many tumors contain supernumerary centrosomes, which contribute to aneuploidy induction via multipolar mitotic spindle formation. As spindle multipolarity leads to cell death, tumor cells developed centrosomal clustering mechanism to prevent multipolar spindle formation by coalescence of multiple centrosomes into two functional spindle poles. Inhibition of centrosome clustering represents a novel strategy for drug development and leads to the formation of multipolar spindles and subsequent cell death. In the present review, we report advances in understanding the biology of centrosomal clustering as well as enlist compounds capable of inducing the formation of multipolar spindles such as indolquinolizines, integrin-linked kinase inhibitors (QLT-0267), noscapinoids (EM011), phthalamide derivatives (TC11), griseofulvin, phenanthridines (PJ-34), CCC1-01, CW069 GF-15, colcemid, nocodazole, paclitaxel, and vinblastine. We also present in silico result of compounds that bind to γ-tubulin under the ambit of centrosomal clustering inhibition. We observed maximum binding efficacy in GF-15, CW069, paclitaxel and larotaxel with GF-15 exhibiting least energy of -8.4 Kcal/mol and 0.7 μM Pki value.
Export Options
About this article
Cite this article as:
D. Bhakta-Guha, M.E.M. Saeed, H.J. Greten and T. Efferth , Dis-organizing Centrosomal Clusters: Specific Cancer Therapy for a Generic Spread?, Current Medicinal Chemistry 2015; 22 (6) . https://dx.doi.org/10.2174/0929867322666141212114529
DOI https://dx.doi.org/10.2174/0929867322666141212114529 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Overcoming Drug Resistance by Enhancing Apoptosis of Tumor Cells
Current Cancer Drug Targets Optimal Management of Prostate Cancer Based on its Natural Clinical History
Current Cancer Drug Targets Design, Synthesis and In-Vitro Evaluation of Polymer-linked Prodrug of Methotrexate for the Targeted Delivery to the Colon
Letters in Drug Design & Discovery Evaluation of In-Vivo Anti-Implantation and In-Vitro Anti-Proliferative Activities of Substituted 3-phenyl-4-phenylvinyl Benzopyranone Derivatives
Letters in Drug Design & Discovery Plant-Made Antibodies: Properties and Therapeutic Applications
Current Medicinal Chemistry Targeting Indoleamine 2,3-dioxygenase (IDO) to Counteract Tumour- Induced ImmuneDysfunction: From Biochemistry to Clinical Development
Endocrine, Metabolic & Immune Disorders - Drug Targets Molecular Targets in Gastrointestinal Stromal Tumors (GIST) Therapy
Current Cancer Drug Targets Structure, Function, and Pathogenesis of SHP2 in Developmental Disorders and Tumorigenesis
Current Cancer Drug Targets Recent Advances in Site Specific Conjugations of Antibody Drug Conjugates (ADCs)
Current Cancer Drug Targets Endocrine Therapy for Advanced Breast Cancer: Beyond Tamoxifen and Aromatase Inhibitors
Current Cancer Therapy Reviews Crocins: The Active Constituents of Crocus Sativus L. Stigmas, Exert Significant Cytotoxicity on Tumor Cells In Vitro
Current Cancer Therapy Reviews The Role of PEDF in Tumor Growth and Metastasis
Current Molecular Medicine Antigenic and Immunogenic Phage Displayed Mimotopes as Substitute Antigens Applications and Limitations
Combinatorial Chemistry & High Throughput Screening Aspirin: from a Historical Perspective
Recent Patents on Cardiovascular Drug Discovery Gamma Linolenic Acid: An Antiinflammatory Omega-6 Fatty Acid
Current Pharmaceutical Biotechnology Editorial: Advances in Epithelial Ovarian Cancer Therapy
Current Pharmaceutical Design Dynamic Contrast-Enhanced MRI in Oncology Drug Development
Current Clinical Pharmacology Brain Drug Delivery Systems for the Stroke Intervention and Recovery
Current Pharmaceutical Design MicroRNAs and the Response of Prostate Cancer to Anti-Cancer Drugs
Current Drug Targets Extracellular Signal-Regulated Kinases Modulate DNA Damage Response - A Contributing Factor to Using MEK Inhibitors in Cancer Therapy
Current Medicinal Chemistry